Understanding Alzheimer’s biomarkers to improve diagnosis and track progression
Official title: Project 1
Funded at Northern California Institute/res/edu · NIH-11395242 · Data updated 2026-11-12
Researchers are studying blood, spinal fluid, and brain imaging clues to better detect Alzheimer’s disease and monitor how it changes over time so future treatments can be targeted and measured more effectively.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northern California Institute/res/edu NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | September 30, 2004 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $523,437 |
| NIH project number | 5U19AG024904-19 |
| Project ID | NIH-11395242 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include individuals at risk for or showing signs of Alzheimer’s disease who are willing to provide biomarker samples (blood, CSF) and undergo imaging and cognitive assessments.
✕Less likely to help
People without Alzheimer’s pathology or who are unable to participate in biomarker testing or imaging may see limited direct benefit.
What this research studies
If you or a loved one has Alzheimer’s concerns, this project looks at how different biomarkers in blood, spinal fluid, and brain scans work together to identify disease early and track its progression. The team uses data from thousands of participants in ongoing studies to find the best combination of biomarkers that predicts who will benefit from treatment and how quickly the disease may advance. The goal is to create scalable, cost-effective methods that researchers can use in future clinical trials to select participants and measure treatment effects. This work could ultimately help tailor interventions based on an individual’s biomarker profile.
Why it matters
Potential benefit: If successful, this work could lead to smarter screening and better-designed trials, speeding the development of effective Alzheimer’s therapies.
How similar studies have gone: Prior large studies like ADNI have shown that combining biomarkers can improve disease prediction and trial design, supporting further development.
Where this research is happening
-
Northern California Institute/res/edu
San Francisco, United States Active
Researchers
- Principal investigator: Tosun-Turgut, Duygu — Northern California Institute/res/edu
- Study coordinator: Tosun-Turgut, Duygu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.